Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) Research & Development (2023 - 2025)

Incannex Healthcare (IXHL) has disclosed Research & Development for 3 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 61.24% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Dec 2025, down 17.65% year-over-year, with the annual reading at $10.7 million for FY2025, 16.55% down from the prior year.
  • Research & Development hit $2.3 million in Q4 2025 for Incannex Healthcare, up from $1.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.4 million in Q2 2024 to a low of $1.1 million in Q3 2025.
  • Historically, Research & Development has averaged $2.7 million across 3 years, with a median of $2.7 million in 2023.
  • Biggest YoY gain for Research & Development was 61.24% in 2025; the steepest drop was 61.33% in 2025.
  • Year by year, Research & Development stood at $2.6 million in 2023, then plummeted by 46.4% to $1.4 million in 2024, then soared by 61.24% to $2.3 million in 2025.
  • Business Quant data shows Research & Development for IXHL at $2.3 million in Q4 2025, $1.1 million in Q3 2025, and $3.7 million in Q2 2025.